Emtricitab/Rilpiviri/Tenof Ala
Brand name: Odefsey
Rank #120 of 500 drugs by total cost
$144.1M
Total Cost
37,441
Total Claims
$144.1M
Total Cost
1,247
Prescribers
$3,849
Cost per Claim
1,024
Beneficiaries
39,998
30-Day Fills
$116K
Avg Cost/Provider
30
Avg Claims/Provider
About Emtricitab/Rilpiviri/Tenof Ala
Emtricitab/Rilpiviri/Tenof Ala (sold as Odefsey) was prescribed 37,441 times by 1,247 Medicare Part D providers in 2023, costing the program $144.1M. At $3,849 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 117 | Dolutegravir/Rilpivirine (Juluca) | $148.9M | 41,081 |
| 118 | Lisinopril (Lisinopril) | $145.8M | 15,744,768 |
| 119 | Ofatumumab (Kesimpta Pen) | $144.6M | 14,774 |
| 120 | Emtricitab/Rilpiviri/Tenof Ala (Odefsey) | $144.1M | 37,441 |
| 121 | Eltrombopag Olamine (Promacta) | $142.8M | 10,876 |
| 122 | Alpha-1-Proteinase Inhibitor (Prolastin C) | $137.9M | 12,352 |
| 123 | Dasatinib (Sprycel) | $136.8M | 10,389 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology